Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 126CNS 13Gynecologic 11Sarcoma 8Gastrointestinal 8Tumor-Agnostic 7Thoracic 7Dermatologic 6Lymphoid 5Head & Neck 5Other solid neoplasm 4Endocrine 3Other hematologic neoplasm 2Genitourinary 2NET 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ribociclib × Other hematologic neoplasm × Clear all
NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
45 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02187783 2019-07-18

SIGNATURE

Novartis

Phase 2 Completed
106 enrolled 16 charts
BreastGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmThoracic

Breast Neoplasms, Leukemia, Lymphoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡